Overall, five G6PD-deficient and 11 G6PD-intermediate patients received tafenoquine, with one reporting symptoms of acute haemolytic anaemia at day 5, which was not considered to be drug related. This evidence concerns the gene G6PD and non-autoimmune hemolytic anemia.